AtriCure (NASDAQ:ATRC – Free Report) had its price target boosted by Oppenheimer from $32.00 to $36.00 in a research report sent to investors on Wednesday, Benzinga reports. They currently have an outperform rating on the medical device company’s stock. Other equities research analysts have also issued research reports about the company. Piper Sandler dropped their […]

AtriCure (NASDAQ:ATRC – Free Report) had its price target increased by UBS Group from $35.00 to $40.00 in a report published on Wednesday, Benzinga reports. The firm currently has a buy rating on the medical device company’s stock. A number of other brokerages have also issued reports on ATRC. StockNews.com upgraded shares of AtriCure from […]

Amazon.com (NASDAQ:AMZN) had its price objective upped by analysts at Wedbush from $225.00 to $250.00 in a note issued to investors on Friday, Benzinga reports. The brokerage currently has an “outperform” rating on the e-commerce giant’s stock. Wedbush’s price target would indicate a potential upside of 26.19% from the company’s current price. Other research analysts […]